The online version of this article (doi:10.1186/1471-2261-14-184) contains supplementary material, which is available to authorized users.
The authors declare that they have no competing interests.
KLW contributed to the study conception and design, contributed to data collection, analysis and interpretation, and drafted the manuscript. DBW revised the manuscript critically for intellectual content. PPG contributed to data analysis and interpretation as well as editing the manuscript for intellectual content. DHS revised the manuscript critically for intellectual content. SO contributed to data collection and revised the manuscript critically for intellectual content. RJP revised the manuscript critically for intellectual content. EMR contributed to the study conception and design, contributed to data analysis and interpretation, and edited the manuscript for intellectual content. All authors read and approved the final manuscript.
Diabetics are known to have inferior outcomes following peripheral vascular interventions. Thiazolidinediones are oral diabetic agents which improve outcomes following coronary bare metal stenting. No studies have been performed evaluating thiazolidinedione use and outcomes following lower extremity endovascular interventions. We hypothesize that diabetic patients taking thiazolidinediones at the time of primary superficial femoral artery (SFA) stenting have fewer reinterventions.
A retrospective review was performed to identify diabetic patients undergoing primary SFA stenting. The unit of analysis was the extremity. The primary outcome was freedom from target lesion revascularization stratified by thiazolidinedione use, evaluated by Kaplan Meier curves and a log rank test. A Cox proportional hazards model was constructed to determine variables associated with freedom from target lesion revascularization.
SFA stents were placed in 138 extremities in 128 diabetic patients between August 1, 2001 and July 15, 2012. Twenty-four patients were taking thiazolidinediones at the time of SFA stenting. All patients taking thiazolidinediones had TASC A or B lesions. Twenty-seven extremities in the non-thiazolidinedione group had TASC C or D lesions and were excluded to control for disease severity. Freedom from target lesion revascularization was significantly higher in diabetics taking thiazolidinediones at 2 years, 88.5% vs. 59.4%, P = 0.02, SE < 10%. Cox modeling identified a protective trend for thiazolidinedione use (thiazolidinedione use HR 0.33, 95% CI 0.09-1.13), whereas critical limb ischemia and insulin use were associated with trends for worse freedom from target lesion revascularization.
This pilot, translation study demonstrates that diabetic patients taking thiazolidinediones at the time of primary SFA stenting have decreased reintervention rates at 2 years. These results may be explained by higher adiponectin levels or other anti-inflammatory effects in patients taking thiazolidinedione. National and regional quality improvement registries should consider collecting information regarding specific diabetic regimens and use of PPAR agonists such as cilostazol and fibrates.
Iida O, Uematsu M, Soga Y, Hirano K, Suzuki K, Yokoi H, Muramatsu T, Inoue N, Nanto S, Nagata S: Timing of the restenosis following nitinol stenting in the superficial femoral artery and the factors associated with early and late restenoses. Catheter Cardiovasc Interv. 2011, 78: 611-617. 10.1002/ccd.23064. CrossRefPubMed
Woudstra P, Damman P, Beijk MA, Grundeken MJ, Harskamp RE, Koch KT, Henriques JP, Baan J, Vis MM, Piek JJ, Tijssen JG, de Winter RJ: Clinical outcomes after bare-metal stenting in diabetic patients with lesions carrying a low risk of restenosis. Catheter Cardiovasc Interv. 2013, 81: 26-33. 10.1002/ccd.24444. CrossRefPubMed
Moussa I, Leon MB, Baim DS, O’Neill WW, Popma JJ, Buchbinder M, Midwall J, Simonton CA, Keim E, Wang P, Kuntz RE, Moses JW: Impact of sirolimus-eluting stents on outcome in diabetic patients: a SIRIUS (SIRolImUS-coated Bx Velocity balloon-expandable stent in the treatment of patients with de novo coronary artery lesions) substudy. Circulation. 2004, 109: 2273-2278. 10.1161/01.CIR.0000129767.45513.71. CrossRefPubMed
Nishio K, Sakurai M, Kusuyama T, Shigemitsu M, Fukui T, Kawamura K, Itoh S, Konno N, Katagiri T: A randomized comparison of pioglitazone to inhibit restenosis after coronary stenting in patients with type 2 diabetes. Diabetes Care. 2006, 29: 101-106. 10.2337/diacare.29.01.06.dc05-1170. CrossRefPubMed
Takagi T, Yamamuro A, Tamita K, Yamabe K, Katayama M, Mizoguchi S, Ibuki M, Tani T, Tanabe K, Nagai K, Shiratori K, Morioka S, Yoshikawa J: Pioglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with type 2 diabetes mellitus: an intravascular ultrasound scanning study. Am Heart J. 2003, 146: E5- CrossRefPubMed
Marx N, Wohrle J, Nusser T, Walcher D, Rinker A, Hombach V, Koenig W, Hoher M: Pioglitazone reduces neointima volume after coronary stent implantation: a randomized, placebo-controlled, double-blind trial in nondiabetic patients. Circulation. 2005, 112: 2792-2798. 10.1161/CIRCULATIONAHA.105.535484. CrossRefPubMed
Ogasawara D, Shite J, Shinke T, Watanabe S, Otake H, Tanino Y, Sawada T, Kawamori H, Kato H, Miyoshi N, Hirata K: Pioglitazone reduces the necrotic-core component in coronary plaque in association with enhanced plasma adiponectin in patients with type 2 diabetes mellitus. Circ J. 2009, 73: 343-351. 10.1253/circj.CJ-08-0699. CrossRefPubMed
Nakayama T, Komiyama N, Yokoyama M, Namikawa S, Kuroda N, Kobayashi Y, Komuro I: Pioglitazone induces regression of coronary atherosclerotic plaques in patients with type 2 diabetes mellitus or impaired glucose tolerance: a randomized prospective study using intravascular ultrasound. Int J Cardiol. 2010, 138: 157-165. 10.1016/j.ijcard.2008.08.031. CrossRefPubMed
Hupfeld CJ, Weiss RH: TZDs inhibit vascular smooth muscle cell growth independently of the cyclin kinase inhibitors p21 and p27. Am J Physiol Endocrinol Metab. 2001, 281: E207-E216. PubMed
Fuentes E, Palomo I: Mechanism of antiplatelet action of hypolipidemic, antidiabetic and antihypertensive drugs by PPAR activation: PPAR agonists: new antiplatelet agents. Vasc Pharmacol. 2014, 62: 162-166. 10.1016/j.vph.2014.05.008. CrossRef
de Dios ST, Bruemmer D, Dilley RJ, Ivey ME, Jennings GL, Law RE, Little PJ: Inhibitory activity of clinical thiazolidinedione peroxisome proliferator activating receptor-gamma ligands toward internal mammary artery, radial artery, and saphenous vein smooth muscle cell proliferation. Circulation. 2003, 107: 2548-2550. 10.1161/01.CIR.0000074040.31731.96. CrossRefPubMed
Matsuda M, Shimomura I, Sata M, Arita Y, Nishida M, Maeda N, Kumada M, Okamoto Y, Nagaretani H, Nishizawa H, Kishida K, Komuro R, Ouchi N, Kihara S, Nagai R, Funahashi T, Matsuzawa Y: Role of adiponectin in preventing vascular stenosis. The missing link of adipo-vascular axis. J Biol Chem. 2002, 277: 37487-37491. 10.1074/jbc.M206083200. CrossRefPubMed
Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, Iwahashi H, Kuriyama H, Ouchi N, Maeda K, Nishida M, Kihara S, Sakai N, Nakajima T, Hasegawa K, Muraguchi M, Ohmoto Y, Nakamura T: Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol. 2000, 20: 1595-1599. 10.1161/01.ATV.20.6.1595. CrossRefPubMed
Moldoveanu E, Mut-Vitcu B, Tanaseanu GR, Marta DS, Manea G, Kosaka T, Vidulescu C, Tanaseanu C: Low basal levels of circulating adiponectin in patients undergoing coronary stenting predict in-stent restenosis, independently of basal levels of inflammatory markers: lipoprotein associated phospholipase A2, and myeloperoxidase. Clin Biochem. 2008, 41: 1429-1433. 10.1016/j.clinbiochem.2008.09.109. CrossRefPubMed
Kitta Y, Takano H, Nakamura T, Kodama Y, Umetani K, Fujioka D, Saito Y, Kawabata K, Obata JE, Mende A, Kobayashi T, Kugiyama K: Low adiponectin levels predict late in-stent restenosis after bare metal stenting in native coronary arteries. Int J Cardiol. 2008, 131: 78-82. 10.1016/j.ijcard.2007.09.004. CrossRefPubMed
Mito T, Miura S, Iwata A, Morii J, Sugihara M, Ike A, Mori K, Kawamura A, Nishikawa H, Zhang B, Saku K: Determination of the cut-off plasma adiponectin level associated with a lower risk of restenosis in patients with stable angina. Coron Artery Dis. 2011, 22: 451-457. 10.1097/MCA.0b013e3283495d43. CrossRefPubMed
Henriksen K, Byrjalsen I, Qvist P, Beck-Nielsen H, Hansen G, Riis BJ, Perrild H, Svendsen OL, Gram J, Karsdal MA, Christiansen C: Efficacy and safety of the PPARgamma partial agonist balaglitazone compared with pioglitazone and placebo: a phase III, randomized, parallel-group study in patients with type 2 diabetes on stable insulin therapy. Diabetes Metab Res Rev. 2011, 27: 392-401. 10.1002/dmrr.1187. CrossRefPubMed
- Retrospective review of superficial femoral artery stenting in diabetic patients: thiazolidinedione use may decrease reinterventions
Karen L Walker
Daniel B Walsh
Philip P Goodney
Samantha A Connell
David H Stone
Richard J Powell
Eva M Rzucidlo
- BioMed Central
Neu im Fachgebiet Kardiologie
Mail Icon II